Capter 11 Filtering in Drug Discovery

Publisher Summary This chapter discusses the concept of filtering in drug discovery. Multiple filters may be incorporated into a definition of drug-likeness and this leads to tradeoffs among compound properties in compounds intended for screening. The optimization of compound properties may require some type of multiparameter optimization scheme in library design. Fingerprint algorithms can be used to guide diversity. Filters also need to be employed in the chemistry synthesis planning process so that good quality compounds are made. Differences in property ranges between oral and injectable drugs are summarized in the chapter. Oral drugs are lower in MWT and have fewer H-bond donors, acceptors, and rotatable bonds. A scheme for separating central nervous system (CNS)- from non-CNS-active drugs in the WDI allowed the discovery of simple parameters relating to passive blood brain barrier (BBB) permeability and the prediction of p-glycoprotein (PGP) affinity. The PGP transporter is a major barrier to the entry of compounds to the CNS. Appropriately determined PGP efflux ratios can be used as a measure of compound affinity to PGP.

[1]  A. Sands,et al.  Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.

[2]  J. Proudfoot,et al.  A structure-permeability study of small drug-like molecules. , 2003, Bioorganic & medicinal chemistry letters.

[3]  Gerhard Müller,et al.  Protein secondary structure templates derived from bioactive natural products – Combinatorial chemistry meets structure-based design , 1998, J. Comput. Aided Mol. Des..

[4]  U Norinder,et al.  Experimental and computational screening models for the prediction of intestinal drug absorption. , 2001, Journal of medicinal chemistry.

[5]  Oliver Zerbe.  BioNMR in drug research , 2003 .

[6]  Ulf Norinder,et al.  Molecular Descriptors Influencing Melting Point and Their Role in Classification of Solid Drugs , 2003, J. Chem. Inf. Comput. Sci..

[7]  J. Proudfoot.  Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. , 2002, Bioorganic & medicinal chemistry letters.

[8]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[9]  Robert P. Sheridan,et al.  The Most Common Chemical Replacements in Drug-Like Compounds , 2002, J. Chem. Inf. Comput. Sci..

[10]  H. Goot.  Trends in Drug Research II. , 1998 .

[11]  Tudor I. Oprea,et al.  Property distribution of drug-related chemical databases* , 2000, J. Comput. Aided Mol. Des..

[12]  P. Hajduk,et al.  Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.

[13]  Igor V. Pletnev,et al.  Drug Discovery Using Support Vector Machines. The Case Studies of Drug‐Likeness, Agrochemical‐Likeness, and Enzyme Inhibition Predictions. , 2004 .

[14]  Nicolas Foloppe,et al.  Drug-like Annotation and Duplicate Analysis of a 23-Supplier Chemical Database Totalling 2.7 Million Compounds , 2004, J. Chem. Inf. Model..

[15]  C. Tice,et al.  Selecting the right compounds for screening: does Lipinski's Rule of 5 for pharmaceuticals apply to agrochemicals? , 2001, Pest management science.

[16]  P. Kinnunen,et al.  Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability. , 2004, Journal of medicinal chemistry.

[17]  Christel A. S. Bergström,et al.  Intestinal Absorption: The Role of Polar Surface Area , 2003 .

[18]  T Mitchell,et al.  Design strategies for building drug-like chemical libraries. , 2001, Current opinion in drug discovery & development.

[19]  M. Hashida,et al.  Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans. , 2001, Biological & pharmaceutical bulletin.

[20]  Gabriele Cruciani,et al.  Surface descriptors for protein-ligand affinity prediction. , 2003, Journal of medicinal chemistry.

[21]  I. Muegge,et al.  Simple selection criteria for drug-like chemical matter. , 2001, Journal of medicinal chemistry.

[22]  Anne Hersey,et al.  Quantitative relationship between rat intestinal absorption and Abraham descriptors. , 2003, European journal of medicinal chemistry.

[23]  Samuel H. Yalkowsky,et al.  Prediction of Drug Solubility by the General Solubility Equation (GSE) , 2001, J. Chem. Inf. Comput. Sci..

[24]  Mark T. D. Cronin,et al.  Modeling Discrimination between Antibacterial and Non‐Antibacterial Activity based on 3D Molecular Descriptors , 2003 .

[25]  W. Bretz,et al.  Red Marine Algae Lithothamnion calcareum Supports Dental Enamel Mineralization , 2023, Marine drugs.

[26]  H Matter,et al.  Computational approaches towards the rational design of drug-like compound libraries. , 2001, Combinatorial chemistry & high throughput screening.

[27]  Yi Li,et al.  In silico ADME/Tox: why models fail , 2003, J. Comput. Aided Mol. Des..

[28]  Christel A. S. Bergström,et al.  Absorption classification of oral drugs based on molecular surface properties. , 2003, Journal of medicinal chemistry.

[29]  G. Bemis,et al.  Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.

[30]  Tudor I. Oprea,et al.  Pharmacokinetically based mapping device for chemical space navigation. , 2002, Journal of combinatorial chemistry.

[31]  C. Hulme,et al.  "Multi-component reactions : emerging chemistry in drug discovery" 'from xylocain to crixivan'. , 2003, Current medicinal chemistry.

[32]  H. Kubinyi.  Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[33]  Kuo-Chen Chou,et al.  Virtual Screening for SARS-CoV Protease Based on KZ7088 Pharmacophore Points , 2004, J. Chem. Inf. Model..

[34]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[35]  Ajay,et al.  Recognizing molecules with drug-like properties. , 1999, Current opinion in chemical biology.

[36]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[37]  Pierre Acklin,et al.  Similarity Metrics for Ligands Reflecting the Similarity of the Target Proteins , 2003, J. Chem. Inf. Comput. Sci..

[38]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[39]  Herbert Waldmann,et al.  From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.

[40]  Jeffrey W. Peng,et al.  Applications of SHAPES screening in drug discovery. , 2002, Combinatorial chemistry & high throughput screening.

[41]  Jun Xu,et al.  Drug-like Index: A New Approach To Measure Drug-like Compounds and Their Diversity , 2000, J. Chem. Inf. Comput. Sci..

[42]  B. Shoichet,et al.  Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.

[43]  Franco Lombardo,et al.  In silico ADME prediction: data, models, facts and myths. , 2003, Mini reviews in medicinal chemistry.

[44]  Maurice Dickins,et al.  Substrate SARs in human P450s. , 2002, Drug discovery today.

[45]  Mark L. Smythe,et al.  Exploring privileged structures: the combinatorial synthesis of cyclic peptides , 2002, J. Comput. Aided Mol. Des..

[46]  Gerard J Kleywegt,et al.  Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. , 2003, Angewandte Chemie.

[47]  H. Vromans,et al.  Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. , 2003, International journal of pharmaceutics.

[48]  W. Pardridge,et al.  Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. , 2003, Current opinion in drug discovery & development.

[49]  Tudor I. Oprea,et al.  Chemical information management in drug discovery: optimizing the computational and combinatorial chemistry interfaces. , 2000, Journal of Molecular Graphics and Modelling.

[50]  Brian K Shoichet,et al.  Kinase inhibitors: not just for kinases anymore. , 2003, Journal of medicinal chemistry.

[51]  Stuart L Schreiber,et al.  A planning strategy for diversity-oriented synthesis. , 2004, Angewandte Chemie.

[52]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[53]  H. Jhoti,et al.  Structure-based screening of low-affinity compounds. , 2002, Drug discovery today.

[54]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[55]  Trudi Wright,et al.  Optimizing the Size and Configuration of Combinatorial Libraries , 2003, J. Chem. Inf. Comput. Sci..

[56]  Mary P. Bradley.  An overview of the diversity represented in commercially-available databases , 2002, J. Comput. Aided Mol. Des..

[57]  T. Guo,et al.  Privileged structure-based combinatorial libraries targeting G protein-coupled receptors. , 2003, Assay and drug development technologies.

[58]  W. Patrick Walters,et al.  Filtering databases and chemical libraries , 2004, Molecular Diversity.

[59]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[60]  U. Norinder,et al.  Computational approaches to the prediction of the blood-brain distribution. , 2002, Advanced drug delivery reviews.

[61]  Herbert Waldmann,et al.  From protein domains to drug candidates – natural products as guiding principles in , 2002 .

[62]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[63]  Gennady M Verkhivker,et al.  Unraveling principles of lead discovery: from unfrustrated energy landscapes to novel molecular anchors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Jürgen Bajorath,et al.  Methods for compound selection focused on hits and application in drug discovery. , 2002, Journal of molecular graphics & modelling.

[65]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[66]  K. Wanner,et al.  Methods and Principles in Medicinal Chemistry , 2007 .

[67]  H. Kolb,et al.  The growing impact of click chemistry on drug discovery. , 2003, Drug discovery today.

[68]  Peter Willett,et al.  Computational methods for the analysis of molecular diversity , 1996 .

[69]  Tudor I. Oprea,et al.  Virtual Screening in Lead Discovery: A Viewpoint† , 2002, Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry.

[70]  G. Müller,et al.  Medicinal chemistry of target family-directed masterkeys. , 2003, Drug discovery today.

[71]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[72]  Alex Polinsky,et al.  10 – HIGH-SPEED CHEMISTRY LIBRARIES: ASSESSMENT OF DRUG-LIKENESS , 2003 .

[73]  Hans Lennernäs,et al.  Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. , 2003, Journal of pharmaceutical sciences.

[74]  Igor V. Pletnev,et al.  Drug Discovery Using Support Vector Machines. The Case Studies of Drug-likeness, Agrochemical-likeness, and Enzyme Inhibition Predictions , 2003, J. Chem. Inf. Comput. Sci..

[75]  D. Fattori,et al.  Molecular recognition: the fragment approach in lead generation. , 2004, Drug discovery today.

[76]  L. Molnár,et al.  Recent advances in the prediction of blood-brain partitioning from molecular structure. , 2003, Journal of pharmaceutical sciences.

[77]  Gavin Harper,et al.  Drug rings database with web interface. A tool for identifying alternative chemical rings in lead discovery programs. , 2003, Journal of medicinal chemistry.

[78]  David J. Craik,et al.  FUNCTIONAL GROUP CONTRIBUTIONS TO DRUG-RECEPTOR INTERACTIONS , 1985 .

[79]  John Davies,et al.  Design of small molecule libraries for NMR screening and other applications in drug discovery. , 2002, Current topics in medicinal chemistry.

[80]  C. Tice.  Selecting the right compounds for screening: use of surface-area parameters. , 2002, Pest management science.

[81]  Marcel L. Verdonk,et al.  The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..

[82]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[83]  Ingrid Pettersson,et al.  Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. , 2003, Journal of medicinal chemistry.

[84]  Robert P Bywater,et al.  Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.

[85]  Target information in lead discovery , 2003 .

[86]  Douglas A. Horton,et al.  The combinatorial synthesis of bicyclic privileged structures or privileged substructures. , 2003, Chemical reviews.

[87]  Franco Lombardo,et al.  Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. , 2004, Journal of medicinal chemistry.

[88]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[89]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[90]  Christopher A. Lepre,et al.  Strategies for NMR Screening and Library Design , 2003 .

[91]  G. Rishton.  Reactive compounds and in vitro false positives in HTS , 1997 .

[92]  Brian Hudson,et al.  Strategic Pooling of Compounds for High-Throughput Screening , 1999, J. Chem. Inf. Comput. Sci..

[93]  J. Blake.  Examination of the computed molecular properties of compounds selected for clinical development. , 2003, BioTechniques.

[94]  Franco Lombardo,et al.  Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. , 2002, Journal of medicinal chemistry.

[95]  Miklos Feher,et al.  Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..

[96]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[97]  Marc Adenot,et al.  Blood-Brain Barrier Permeation Models: Discriminating between Potential CNS and Non-CNS Drugs Including P-Glycoprotein Substrates , 2004, J. Chem. Inf. Model..

[98]  S. Teague.  Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.

[99]  Ian A. Watson,et al.  Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.

[100]  Arthur A. Patchett,et al.  Chapter 26. Privileged structures — An update , 2000 .

[101]  Tudor I. Oprea.  Current trends in lead discovery: Are we looking for the appropriate properties? , 2002, J. Comput. Aided Mol. Des..